Deciphering hepatoma cell resistance to tyrosine kinase inhibitors: insights from a Liver-on-a-Chip model unveiling tumor endothelial cell mechanisms-Reference-Cited by-同舟云学术

Deciphering hepatoma cell resistance to tyrosine kinase inhibitors: insights from a Liver-on-a-Chip model unveiling tumor endothelial cell mechanisms

Published:2024 Issue:15 Volume:24 Page:3668-3678
ISSN:1473-0197
Container-title:Lab on a Chip
language:en
Short-container-title:Lab Chip

Author:

Poddar Madhu Shree¹,Chu Yu-De²³⁴^ORCID,Yeh Chau-Ting²³⁴,Liu Cheng-Hsien¹⁵⁶^ORCID

Affiliation:

1. Institute of Nanoengineering and Microsystems, National Tsing Hua University, Hsinchu, 30044, Taiwan, Republic of China

2. Liver Research Center, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan, Republic of China

3. Molecular Medicine Research Center, Chang Gung University, Taoyuan 333, Taiwan, Republic of China

4. Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan, Republic of China

5. Department of Power Mechanical Engineering, National Tsing Hua University, Hsinchu 30044, Taiwan, Republic of China

6. College of Semiconductor Research, National Tsing Hua University, Hsinchu 30044, Taiwan, Republic of China

Abstract

Tumor angiogenesis on microfluidic chips reveals treatments, advances therapeutic strategies and helps to understand tumor drug-resistance mechanisms.

Funder

National Science and Technology Council

National Tsing Hua University

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/LC/D4LC00238E

Reference54 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Effective Inhibition of Xenografts of Hepatocellular Carcinoma (HepG2) by Rapamycin and Bevacizumab in an Intrahepatic Model

3. Epidemiology and Management of Hepatocellular Carcinoma

4. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

5. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study